OrthoPediatrics (NASDAQ:KIDS) Price Target Raised to $42.00 at Needham & Company LLC

OrthoPediatrics (NASDAQ:KIDS) had its price target raised by Needham & Company LLC from $37.00 to $42.00 in a research note published on Tuesday, Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

Several other equities research analysts also recently issued reports on KIDS. Truist Financial downgraded shares of OrthoPediatrics from a buy rating to a hold rating and cut their target price for the company from $39.00 to $31.00 in a research note on Thursday, January 25th. JMP Securities reaffirmed a market outperform rating and issued a $50.00 price objective on shares of OrthoPediatrics in a research report on Tuesday.

OrthoPediatrics Stock Performance

Shares of NASDAQ KIDS opened at $34.70 on Tuesday. The stock has a market capitalization of $825.51 million, a PE ratio of -37.72 and a beta of 1.16. OrthoPediatrics has a 52 week low of $23.10 and a 52 week high of $48.47. The stock has a 50 day moving average price of $28.80 and a 200 day moving average price of $29.04. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.90 and a current ratio of 5.44.

OrthoPediatrics (NASDAQ:KIDS) last released its earnings results on Wednesday, March 6th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.05. OrthoPediatrics had a negative net margin of 14.10% and a negative return on equity of 5.03%. The business had revenue of $37.61 million during the quarter, compared to analysts’ expectations of $37.59 million. Analysts predict that OrthoPediatrics will post -1.34 earnings per share for the current fiscal year.

Insider Buying and Selling at OrthoPediatrics

In other news, CEO David R. Bailey sold 3,213 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $27.59, for a total transaction of $88,646.67. Following the completion of the sale, the chief executive officer now owns 139,384 shares in the company, valued at $3,845,604.56. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, CEO David R. Bailey sold 3,213 shares of OrthoPediatrics stock in a transaction on Monday, March 11th. The stock was sold at an average price of $27.59, for a total transaction of $88,646.67. Following the completion of the sale, the chief executive officer now owns 139,384 shares of the company’s stock, valued at $3,845,604.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Fred Hite sold 3,195 shares of the business’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $27.59, for a total transaction of $88,150.05. Following the completion of the sale, the chief financial officer now directly owns 94,072 shares of the company’s stock, valued at approximately $2,595,446.48. The disclosure for this sale can be found here. Insiders have sold a total of 17,253 shares of company stock valued at $477,375 in the last three months. 31.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in KIDS. Quantbot Technologies LP boosted its stake in shares of OrthoPediatrics by 180.8% in the first quarter. Quantbot Technologies LP now owns 7,091 shares of the company’s stock valued at $207,000 after buying an additional 4,566 shares during the period. BNP Paribas Financial Markets raised its holdings in OrthoPediatrics by 85.1% in the 1st quarter. BNP Paribas Financial Markets now owns 12,414 shares of the company’s stock valued at $362,000 after acquiring an additional 5,707 shares in the last quarter. Conestoga Capital Advisors LLC raised its holdings in OrthoPediatrics by 7.3% in the 1st quarter. Conestoga Capital Advisors LLC now owns 48,653 shares of the company’s stock valued at $1,419,000 after acquiring an additional 3,300 shares in the last quarter. Wasatch Advisors LP lifted its position in shares of OrthoPediatrics by 21.2% during the 1st quarter. Wasatch Advisors LP now owns 501,310 shares of the company’s stock valued at $14,618,000 after acquiring an additional 87,657 shares during the period. Finally, Wellington Management Group LLP acquired a new stake in shares of OrthoPediatrics during the 4th quarter worth $10,214,000. 69.05% of the stock is owned by institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.